REVELATION BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
REVELATION BIOSCIENCES, INC. (REVB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $401.42 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $401.42K, a 45881.33% increase year-over-year.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $471.00K, a 110.78% increase year-over-year.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $874.00, a 97.28% decline year-over-year.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $873.00, a 97.28% decline year-over-year.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $595.37K, a 252.60% increase from fiscal 2024.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $168.85K, a 8.43% increase from fiscal 2023.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $155.72K, a 48.29% decline from fiscal 2022.
- REVELATION BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $301.12K, a 36.05% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $401.42K 10-Q · filed 2026-08-06 | $872.41K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $471.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $595.37K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $874.00 10-Q · filed 2025-11-06 | $1.75K derived: sum of 2 quarters · filed 2026-08-06 | $225.20K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $873.00 10-Q · filed 2026-08-06 | $224.33K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $223.46K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $168.85K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $32.09K 10-Q · filed 2025-11-06 | $64.19K derived: sum of 2 quarters · filed 2025-11-06 | $96.28K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $32.09K 10-Q · filed 2025-11-06 | $64.19K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $32.09K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $155.72K 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $32.10K 10-Q · filed 2024-11-08 | $91.53K derived: sum of 2 quarters · filed 2024-11-08 | $123.63K derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $59.44K 10-Q · filed 2024-11-08 | $91.53K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $32.09K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $301.12K 10-K/A · filed 2024-09-23 | |||
| 2022-09-30 | $40.67K 10-Q · filed 2023-11-09 | $130.86K derived: sum of 2 quarters · filed 2023-11-09 | $268.75K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $90.19K 10-Q · filed 2023-11-09 | $228.08K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $137.89K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $470.88K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $131.32K 10-Q · filed 2022-11-10 | $262.64K derived: sum of 2 quarters · filed 2022-11-10 | $364.97K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $131.32K 10-Q · filed 2022-11-10 | $233.65K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $102.33K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |